-
AztraZeneca told investors on Monday that a U.S. judge refused to grant a request to delay the launch of generic versions of its antidepressant Seroquel.
-
Here's what's making health news this morning: Court Rejects Patents on Medical Tests: (WSJ) The Supreme Court jolted the biotechnology industry with a unanimous ruling that threw out two medical-testing patents and suggested companies need to do more to prove their discoveries are really new...
-
Also: age and gender differences in heart-attack symptoms; Supreme Court won't hear J&J's patent plea against Abbott; a study of raw milk and food-borne illness outbreaks.
-
However, these projections come with an asterisk: they "estimate what would happen with the rapid availability and timely uptake of generic atorvastatin."
-
Also: teen "sexting" not as common as you might think; Supreme Court hears medical-test patent case; anti-abortion tactic dispute.
-
Merck tried three times to get Mevacor cleared by the FDA -- and three times, it was rejected, most recently in 2008.
-
This is a good deal for developing nations getting drugs at an affordable price. This makes Johnson and Johnson the first pharma company to license generic copies before approval is even given. J and J licensed the drug for use in 48 countries listed as least developed countries to include...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sun, Jan 30 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Pills, FDA, Generic Drugs, Patents, Johnson and Johnson, AIDS, licence, Tibotec, regulators
-
For a little history here on ED drugs, not too long ago the US Copyright office declined to give Pfizer the trademark on Viagra, saying it was too close to Horney goat weed, and hey if nothing else you have to love the name of this herb. I had actually mentioned this product as one of the alternatives...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Jun 21 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Coffee, court cases, herb, trademark
-
This is interesting and a deal was made here so Teva has a 180 day exclusive. On one hand we have Teva in court with Merck over Singulair and on the other hand here, they get a deal. Teva is probably the most aggressive pharma company today with challenging patents. Merck and Singulair –...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Apr 7 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Hypertension, Generic Drugs, Merck, Patents, Teva, Intellutual property, Cozaar, Hyzaar
-
The FDA has given Teva tentative approval to begin selling a generic version in 2012. Teva states the patent for 2019 is invalid and a generic product will not .png?imgmax=800" width="153" height="59" alt="" />infringe. This goes back to 2004 when Teva notified Pfizer of their intention. ...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Apr 2 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Teva, Coffee, court cases, herb, trademark
-
Here’s some more healthcare money being spent on legal suits over ED drugs. You know if pharma keeps up with all these extensive legal battles it might begin to start depleting some profits and of course it keeps the cost up there for us. There’s an appeal process too and this goes back to...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Feb 16 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Coffee, court cases, herb, trademark
-
Legal suits are still ramped with drug companies in the court rooms, this one has to be one of the largest settlements I am aware of, over a billion dollar infringement over the patent, or aka Intellectual Property as sometimes referred to today. The two drugs in question were Humira from Abbott...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jun 30 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Prescriptions, Patents, Johnson and Johnson, Intellectual property, Lawsuits, Abbott Labs
-
The latest battle is with Pfizer and Mylan, a generic drug manufacturer going to court. Mylan is ready to go to market but not until Pfizer gives the go ahead and that date is in the year 2017. Pfizer is not the only one being challenged by any means, Merck has their issues with Singulair...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jun 16 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Generic Drugs, Merck, Pfizer, Patents, Biosimilars, Teva, intilectual property, court case, follow me drugs, Mylan
-
Teva has certainly been busy with a number of legal challenges of late, yesterday one filed against Amgen too. The challenge of intellectual property in the pharmaceutical business is certainly heating up. Teva produces generic drugs for the most part and states their efforts are coming...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, May 29 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Biotech, FDA, Generic Drugs, Merck, kidney disease, Patents, Intellectual property, Teva, Biosimilar Drugs, Singulair, Sensipar
-
Teva wants to sell a generic version of the product and claims Amgen is using it’s patented technology to create Sensipar and now it wants Amgen to pay and halt production. This is unusual to somewhat see the tables turned here, usually it is the named brand going after a generic. This case...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, May 29 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Biotech, FDA, Generic Drugs, kidney disease, Patents, Amgen, Intellectual property, Teva, Biosimilar Drugs, Sensipar